Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy

Radiology and Oncology

Mojca Unk^2¹  Martina Vrankar^1² 

[1] Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia^2;Department of Radiotherapy, Institute of Oncology Ljubljana, Ljubljana, Slovenia^1

关键词: symptomatic pseudoprogression;    atypical response;    immunotherapy;    lung cancer;   

DOI  :  10.2478/raon-2018-0037

学科分类：肿瘤学

来源: Onkoloski Institut Ljubljana / Institute of Oncology Ljubljana

【 摘 要 】

BackgroundUncommon response during immunotherapy is a new challenging issue in oncology practice. Recently, new criteria for evaluation of response to immunotherapy immune response evaluation criteria in solid tumors (iRECIST) were accepted. According to iRECIST, worsening of performance status (PS) accompanied to pseudoprogression reflects most probably the true progression of the malignant disease.

【 授权许可】

Unknown